[Individualization of polychemotherapy for stage III breast cancer based on immunologic status].
Immunologic response was studied in 91 cases of stage III breast cancer who received a CFMVP polychemotherapy. 23 patients were given decaris for immunostimulation. All cases showed a significant decrease in cellular immunity. CFMVP-treated patients showing a decrease of 30% and more should receive 300 mg of decaris twice a week for 3 weeks.